lifestyle.thriveinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvation Bio, Inc.
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
April 1, 2026
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 26, 2026
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
March 17, 2026
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 2, 2026
Nuvation Bio to Participate in Upcoming Investor Conferences
February 25, 2026
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026
February 17, 2026